A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Insulin glargine (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Sanofi
- 23 Jan 2017 Results published in the Diabetes Care: THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION.
- 11 Nov 2016 Results published in a Sanofi media release.
- 19 Sep 2014 Primary endpoint (Percent (%) of time in target plasma glucose range (80-140mg/dL)) has been met.